{"disease":{"id":"diffuse-large-b-cell-lymphoma-unclassifiable","name":"diffuse large b cell lymphoma unclassifiable"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT00856388","title":"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT02636322","title":"Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03150329","title":"Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT04665765","title":"Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":41,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT05821088","title":"Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"David Bond, MD","has_results":false},{"nct_id":"NCT03749018","title":"Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"David Bond, MD","has_results":false},{"nct_id":"NCT03704714","title":"Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"SUSPENDED","enrollment_count":30,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT07097363","title":"Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"University of Washington","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}